What is lorlatinib? Analysis of indications and mechanism of action

Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI), which is a targeted therapy drug and is mainly used to treat AL K (anaplastic lymphoma kinase)-positive and ROS1-positive non-small cell lung cancer (NSCLC). The drug was developed by Pfizer and is specifically designed to overcome the resistance problems that occur with early ALK inhibitors (such as crizotinib, alectinib, etc.). It is currently one of the more advanced targeted drugs in the treatment of ALK-positive lung cancer.

The main targets of lorlatinib are ALK and ROS1 fusion proteins. These fusion proteins are abnormally expressed in some patients with non-small cell lung cancer, driving the continued proliferation and survival of tumor cells. Lorlatinib can efficiently penetrate the blood-brain barrier and inhibit the kinase activity of ALK or ROS1 fusion protein, thereby blocking the signal transduction mediated by it and promoting tumor cell apoptosis. It also has good anti-tumor activity in the central nervous system and is suitable for patients with brain metastases.

In terms of clinical indications, lorlatinib is generally used in patients with ALK-positive metastatic NSCLC, especially in the setting of drug resistance or disease progression after receiving one or more ALK TKI treatments (such as crizotinib, alectinib, brigatinib). In addition, it is also suitable for some ROS1positive NSCLC patients, especially as a second-line or later-line treatment option after failure of other ROS1 inhibitor treatments.

One of the advantages of lorlatinib is that it is active against a variety of drug-resistant mutations, able to solve the multiple mutation problems caused by the use of early ALK inhibitors, and significantly control brain lesions. But at the same time, it may also bring about some central nervous system-related side effects, such as mood changes, cognitive impairment, hyperlipidemia, etc. Therefore, patients need close monitoring and individualized dose adjustment during use to ensure maximum efficacy and minimize adverse reactions.

Reference link:https://www.lorbrena.com/